Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2023-06-13 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
关于控股股东部分股份质押及解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the pledge and release of shares by the controlling shareholder of the company. It details the number of shares pledged, the proportion of total shares, pledge start and end dates, and the pledge purposes. There is no financial performance data, no discussion of earnings, no management commentary on results, and no mention of report attachments. The document is a regulatory disclosure about share pledging activities by a major shareholder, which fits the category of Major Shareholding Notification (MRQ). The document length is short and focused solely on share pledge information, confirming it is not a full financial report or earnings release.
2023-06-13 Chinese
2022年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is titled as an announcement regarding the implementation of the 2022 annual profit distribution (dividend) plan by Enwei Pharmaceutical Co., Ltd. It details the dividend amount, the record date, the ex-dividend date, and the method of dividend distribution. It also references the shareholders' meeting approval of the profit distribution plan and related resolutions. The document is short (1986 characters) and focuses solely on the dividend distribution details without containing any financial statements or comprehensive financial analysis. Therefore, it is not an Annual Report or Interim Report but a Notice of Dividend Amount. This fits the definition of a Notice of Dividend Amount (DIV) filing.
2023-05-15 Chinese
2022年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2022 年年度股东大会决议公告" which translates to "2022 Annual General Meeting Resolution Announcement." It details the convening, attendance, and voting results of the 2022 Annual General Meeting (AGM) of the company 恩威医药股份有限公司. The document includes resolutions passed at the AGM, voting percentages, and legal opinions on the meeting's validity. It does not contain the full annual report or financial statements but rather the official announcement of the AGM resolutions and voting outcomes. The document length is 4633 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-05-12 Chinese
北京金杜（成都）律师事务所关于恩威医药股份有限公司2022年年度股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2022 Annual General Meeting (AGM) of Enwei Pharmaceutical Co., Ltd. It details the procedures of the AGM, attendance, voting results on various resolutions including the 2022 annual report, financial statements, profit distribution plan, and other corporate matters. The document focuses on the legality and validity of the AGM process and voting outcomes rather than presenting the financial report itself. It is not the annual report or financial statements but a legal opinion related to the AGM. Therefore, this document is best classified as Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports official voting results from the AGM.
2023-05-12 Chinese
中信证券股份有限公司关于恩威医药股份有限公司2022年度持续督导工作现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2022年度持续督导工作现场检查报告" which translates to "2022 Annual Continuous Supervision On-site Inspection Report" by the sponsor (中信证券股份有限公司) for the company 恩威医药股份有限公司. The content details the on-site inspection of governance, internal control, information disclosure, protection of company interests, use of raised funds, performance, shareholder commitments, and other important matters for the year 2022. It includes detailed findings and compliance checks but does not contain full financial statements or comprehensive annual financial performance data. It is a standalone audit or inspection report related to internal controls and governance rather than a full Annual Report (10-K) or Interim Report (IR). The document length is 4205 characters, which is relatively short but contains substantive inspection content, not just an announcement or certification. Therefore, it fits best under Audit Report / Information (AR). FY 2022
2023-05-05 Chinese
中信证券股份有限公司关于恩威医药股份有限公司2022 年度跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a "2022年度跟踪报告" (2022 Annual Tracking Report) issued by 中信证券股份有限公司 (CITIC Securities Co., Ltd.) regarding 恩威医药股份有限公司 (Enwei Pharmaceutical Co., Ltd.). It details the sponsor's work overview, supervision of company governance, compliance with disclosure requirements, and regulatory measures taken during the year 2022. The content includes detailed descriptions of the sponsor's review activities, internal control supervision, regulatory sanctions, and company commitments. The document is substantive and contains detailed monitoring and compliance information rather than just an announcement or a brief summary. It is not a full annual report (10-K) of the company itself but rather a sponsor's tracking report on the company for the year. This type of document is best classified as a Regulatory Filing (RNS) because it is a compliance and supervisory report related to regulatory oversight and sponsor duties, not a financial report or earnings release. The document length is 4569 characters, which is substantive enough to be a full report rather than a mere announcement. Therefore, the best fit is Regulatory Filings (RNS).
2023-05-05 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.